Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129818 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00129818: Completed Phase 4 study, sponsored by Novartis.
NCT00129818 is a Phase 4 study that has completed, run by Novartis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00129818, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
Interventions
- DRUG Famciclovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
What the finished NCT00129818 record still lists
NCT00129818 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Famciclovir is the first listed.
NCT00129818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00129818 about?
NCT00129818 is a clinical study titled "A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding". The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
What is the current status of trial NCT00129818?
This trial is currently completed. It is a Phase 4 study. The study started on 2004-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00129818?
The interventions under investigation include: Famciclovir (DRUG).
Who is sponsoring clinical trial NCT00129818?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia